Roche Diagnostics
Basel, Basel-City, Switzerland · Biotechnology, Other · 103,000 employees
Roche Diagnostics is a global leader in in vitro diagnostics and a pioneer in personalized healthcare. The company develops innovative diagnostic solutions that enable better patient care. With a strong presence in oncology, Roche has a comprehensive pipeline of diagnostic tools and therapies. It is committed to improving patient outcomes through advanced diagnostic technologies.
Recent signals
- Jul 01, 2026: Acquired Roche Diagnostics to acquire PathAI for $1.05 billion
- Jun 08, 2026: Roche and Nurix Therapeutics enter into a $2.3 billion partnership to co-develop bexobrutideg for B-cell malignancies.
- May 25, 2026: Acquired Roche to acquire PathAI for digital pathology expansion
- May 08, 2026: Acquired Roche acquires PathAI for $1.05 billion deal
- Mar 24, 2026: Launched Roche launches the cobas eplex respiratory pathogen panel 3 to aid in diagnosing respiratory infections.
- Oct 06, 2025: Launched Roche launches a new Chronic Kidney Disease (CKD) algorithm panel as part of its navify® Algorithm Suite.
- Mar 12, 2025: Roche and Zealand Pharma Partner to Develop Obesity Treatment Portfolio
- Jan 31, 2025: Roche Pharma India Appoints Rajwinder Mehdwan as Country General Manager
See plans & pricing → Track Roche Diagnostics’s funding, hiring, and signals — with verified contacts — on Fundz.